---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-294936"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2023-12-14T23:59:59+00:00"
generated_at: "2026-06-07T12:59:10.783566+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# MindMed Phase 2b MM-120 in GAD meets primary endpoint, 7.6-point HAM-A improvement vs placebo

## Summary
- MM-120 100 µg achieved 21.3-point HAM-A reduction vs 13.7 placebo (p=0.0004, Cohen's d=0.88) at Week 4 after single dose.
- Clinical response rate 78% (100/200 µg) and remission 50% (100 µg) at Week 4; CGI-S improved from 'markedly ill' to 'borderline'.
- Well-tolerated with mostly mild-moderate AEs on dosing day; 97.5% completion in high-dose groups with no AE discontinuations.
- Plans End-of-Phase 2 meeting with FDA in H1 2024 and initiation of Phase 3 program in H2 2024; 12-week data expected Q1 2024.

## SEC filing metadata
- accession: 0001193125-23-294936
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2023-12-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000119312523294936/0001193125-23-294936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000119312523294936/d605082d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-294936
- JSON: https://secwatch.observer/filing/0001193125-23-294936.json
- Plain text: https://secwatch.observer/filing/0001193125-23-294936.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.